Abstract
Severe traumatic brain injury (TBI) is associated with high rates of mortality and long-term disability linked to neurochemical abnormalities. Although purine-derivatives play important roles in TBI pathogenesis in preclinical models, little is known about potential changes in purine levels and their implications in human TBI. We assessed cerebrospinal fluid (CSF) levels of purines in severe TBI patients as potential biomarkers that predict mortality and long-term dysfunction. This was a cross-sectional study performed in 17 severe TBI patients (Glasgow Coma Scale < 8) and 51 controls. Two to four hours after admission to ICU, patients were submitted to ventricular drainage, and CSF collection for quantification of adenine and guanine purine-derivatives by HPLC. TBI patients survival was followed up to 3 days from admission. A neurofunctional assessment was performed through modified Rankin Scale (mRS) two years after ICU admission. Purine levels were compared between control and TBI patients, and between surviving and non-surviving patients. Relative to controls, TBI patients presented increased CSF levels of GDP, guanosine, adenosine, inosine, hypoxanthine, and xanthine. Further, GTP, GDP, IMP, and xanthine levels were different between surviving and non-surviving patients. Among the purines, guanosine was associated with improved mRS (p=0.042; r= −0.506). Remarkably, GTP displayed predictive value (AUC=0.841, p=0.024) for discriminating survival vs. non-survival patients up to three days from admission. These results support TBI-specific purine signatures, suggesting GTP as a promising biomarker of mortality, and guanosine as an indicator of long-term functional disability.
Highlights
CSF levels of guanosine, GDP, adenosine, inosine, hypoxanthine, and xanthine are increased in severe TBI patients.
GTP, GDP, IMP and xanthine levels were different between surviving and non-surviving patients.
Guanosine was associated to improved neurological outcomes two years after TBI.
CSF GTP levels at admission predicted patient death.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by FAPERGS #1010267, FAPERGS/PPSUS#17/2551-0001, FAPERGS/PRONEX#16/2551-0000499-4, Programa de Internacionalização de Ciencia FAPERGS/CAPES #19/25510000717-5, Program Science without Borders CNPQ #4011645/2012-6, and CNPq INNT #5465346/2014-6. Also, this research was made available with the support from National Institutes of Health grants R01NS092398, R01NS038104, R01NS094003, R01EB021293, Paul G. Allen Family Foundation, and the PA Consortium on Traumatic Brain Injury 4100077083.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Hospital Cristo Redentor Institutional Ethics committee gave ethical approval for this work (project number 0038.0.164.165-05)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Complete address for authors: Nathan Ryzewski Strogulski, MSc, Laboratory of Neurotrauma and Biomarkers, Departamento de Bioquímica, ICBS, Universidade Federal do Rio Grande do Sul, UFRGS, Rua Ramiro Barcelos 2600, anexo, Bairro Santana, Porto Alegre, RS, Brasil, CEP 90035-003, Phone: + 55 51 33085557, Fax: + 55 51 33085540, Email: n.strogulski{at}gmail.com
Marco Antônio Stefani, MD, PhD, Laboratory of Neuroanatomy, Departamento de Ciências Morfológicas, ICBS, Universidade Federal do Rio Grande do Sul, UFRGS, Rua Sarmento Leite 500, Bairro Centro Histórico, Porto Alegre, RS, Brasil, CEP 90050170, Phone: +55 51 33083146, Email: marco.stefani{at}ufrgs.br
Ana Elisa Böhmer, PhD, Laboratory of Neurotrauma and Biomarkers, Departamento de Bioquímica, ICBS, Universidade Federal do Rio Grande do Sul, UFRGS, Rua Ramiro Barcelos 2600, anexo, Bairro Santana, Porto Alegre, RS, Brasil, CEP 90035-003, Phone: + 55 51 33085557, Fax: + 55 51 33085540, Email: anaelisab{at}gmail.com
Gisele Hansel, PhD, Neuroinflammation and Neuroimmunology Laboratory Instituto de Cérebro do Rio Grande do Sul, Pontifícia Universidade Católica do Rio Grande do Sul, PUCRS, Avenida Ipiranga 6690, Prédio 63, Bairro Jardim Botânico, Porto Alegre, RS, Brasil, CEP 90610-000, Phone:+55 51 3320 5287, Fax: +55 51 3320 3841, Email: gihansel{at}gmail.com
Marcelo S. Rodolphi, MSc, Laboratory of Neurotrauma and Biomarkers, Departamento de Bioquímica, ICBS, Universidade Federal do Rio Grande do Sul, UFRGS, Rua Ramiro Barcelos 2600, anexo, Bairro Santana, Porto Alegre, RS, Brasil, CEP 90035-003, Phone: + 55 51 33085557, Fax: + 55 51 33085540, Email: marcsalimen{at}gmail.com
Afonso Kopczynski, BSc, Laboratory of Neurotrauma and Biomarkers, Departamento de Bioquímica, ICBS, Universidade Federal do Rio Grande do Sul, UFRGS, Rua Ramiro Barcelos 2600, anexo, Bairro Santana, Porto Alegre, RS, Brasil, CEP 90035-003, Phone: + 55 51 33085557, Fax: + 55 51 33085540, Email: afonsokcarvalho{at}gmail.com
Vitória Girelli de Oliveira, Laboratory of Neurotrauma and Biomarkers, Departamento de Bioquímica, ICBS, Universidade Federal do Rio Grande do Sul, UFRGS, Rua Ramiro Barcelos 2600, anexo, Bairro Santana, Porto Alegre, RS, Brasil, CEP 90035-003, Phone: + 55 51 33085557, Fax: + 55 51 33085540, Email: vvitoriagirelli{at}gmail.com
Eduarda Tanus Stefani, Laboratory of Neuroanatomy, Departamento de Ciências Morfológicas, ICBS, Universidade Federal do Rio Grande do Sul, UFRGS, Rua Sarmento Leite 500, Bairro Centro Histórico, Porto Alegre, RS, Brasil, CEP 90050170, Phone: +55 51 33083146, Email: eduardatstefani{at}gmail.com
Juliana Vinadé Portela, Laboratory of Neurotrauma and Biomarkers, Departamento de Bioquímica, ICBS, Universidade Federal do Rio Grande do Sul, UFRGS, Rua Ramiro Barcelos 2600, anexo, Bairro Santana, Porto Alegre, RS, Brasil, CEP 90035-003, Phone: + 55 51 33085557, Fax: + 55 51 33085540, Email: juliana1vp{at}gmail.com
Jean Pierre Oses, PhD, Instituto de Ciências Biológicas, Universidade Federal do Rio Grande, UFRG, Av. Itália, Km 8, Campus Carreiros, Rio Grande, RS, Brasil, CEP: 96203-900, Phone: +55 53 3233 6848, Fax: +55 53 3233 6848, Email: jean.pierre.oses{at}gmail.com
Andre P Schmidt, MD, PhD, Department of Anesthesia and Perioperative Medicine, Hospital de Clínicas de Porto Alegre, HCPA, UFRGS, Rua Ramiro Barcelos, 2350, Bairro Santana, Porto Alegre, RS, Brasil, CEP 90035-003, Phone: +55 51 33598226, Fax: +55 51 33598226, Email: apschmidtus{at}yahoo.com
Douglas H. Smith, MD, Penn Center for Brain Injury and Repair and Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, UPENN, 105 Hayden Hall, 3320 Smith Walk, Philadelphia, PA, USA., Zip code: 19104-6316, Tel. +1 215-8980881, Fax. +1 215-5733808105, Email: smithdou{at}pennmedicine.upenn.edu
Data Availability
All data produced in the present study are available upon reasonable request to the authors